CureGene Begins U.S. Pivotal Trial for Antiplatelet Drug Evategrel

Evategrel, or CG-0255, represents a departure from standard treatments like clopidogrel by utilizing a proprietary thiol-hydrolyzing prodrug design. By relying on hydrolase enzymes rather than the CYP450 pathway, the drug avoids common issues such as high inter-patient variability and resistance, which currently impacts nearly 60% of East Asian patients. The ongoing trial evaluates both intravenous and oral formulations, positioning the drug for use in acute settings like myocardial infarction and ischemic stroke.

Clinical data indicates that the agent achieves peak antiplatelet effects in under 15 minutes for intravenous delivery and under 30 minutes for oral administration. Furthermore, the required clinical dose is reportedly 1% of the standard clopidogrel dosage, a reduction that aims to minimize bleeding risks and drug-drug interactions. Dr. Gongxin He, founder and CEO of CureGene, noted that the dual-formulation design is intended to reshape existing therapeutic standards. With synchronized development underway in both the U.S. and China, the company anticipates regulatory submissions as early as 2027.